TOUR006 - 50 MG

DRUG2 trials

Sponsors

Tourmaline Bio, Inc., Tourmaline Bio, Inc., a Novartis Company

Conditions

C-Reactive ProteinChronic Kidney DiseasesChronic Kidney InsufficiencyChronic Renal DiseasesChronic Renal InsufficiencyHigh Sensitivity C-Reactive ProteinHs-CRPKidney Insufficiency, Chronic

Phase 2

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

Active, not recruitingNCT06088979

Tourmaline Bio, Inc.Thyroid Eye Disease

Start: 2024-02-19End: 2027-09-01Updated: 2026-04-23

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

CompletedNCT06362759

Tourmaline Bio, Inc., a Novartis CompanyChronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases +6

Start: 2024-05-15End: 2025-12-04Updated: 2026-08-11

Related Papers

Abstract 4363200: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Monthly or Quarterly Subcutaneous Administration of the Interleukin-6 Inhibitor Pacibekitug in Patients With Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease: 90-Day Analyses from TRANQUILITY

Circulation2025-11-03